20,000 genes analyzed
Average 100X Coverage
| ONCOLOGY TESTS | |||||||
|---|---|---|---|---|---|---|---|
| CL-NGS-01 | SENsi-TvR Actionable solid tumor mutation panel | 23 Key clinically validated genes for actionable somatic mutations in solid tumors. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 40000 |
| CL-NGS-02 | SENsi-TvR BRCA1 and BRCA2 Panel | Complete BRCA1 & BRCA2 Gene Coverage for breast and ovarian cancer malignancies | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 25000 |
| CL-NGS-03 | SENsi-TvR BRCA1 and BRCA2 Plus Panel | Complete BRCA1, BRCA2 PLUS CDH1, PALB2, PTEN and TP53 genes commonly mutated in human breast and ovarian cancer samples and involved in breast and ovarian cancer development and progression. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 30000 |
| CL-NGS-04 | SENsi-TvR Breast Cancer Panel | 93 key genes most commonly mutated in human breast cancer subtypes & heterogeneity. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 40000 |
| CL-NGS-05 | SENsi-TvR Colorectal Cancer Panel | 71 key genes most commonly mutated in human colorectal including tumor suppressor gene adenomatosis polyposis coli & β-catenin (CTNNB1) mutation or mutations of genes further upstream in the wnt signaling pathway. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 40000 |
| CL-NGS-07 | SENsi-TvR Lung Cancer Panel | 72 genes most commonly mutated in human lung cancer:covering both small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 40000 |
| CL-NGS-08 | SENsi-TvR Ovarian Cancer Panel | 32 Key genes for Ovarian cancer covering both Type I tumors & type II tumors amd their subtypes. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 40000 |
| CL-NGS-09 | SENsi-TvR Prostate Cancer Panel | 32 key genes most commonly mutated in human prostate responsible for prostate cancer to progress and become invasive. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 40000 |
| CL-NGS-10 | SENsi-TvR Gastric Cancer Panel | 29 Key genes most commonly mutated in human gastric cancer& responsible for progression and invasion to other tissues. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 40000 |
| CL-NGS-13 | SENsi-TvR Comprehensive Cancer Panel | 275 genes most commonly mutated in cancers and involved in cancer development and progression. Mutations in these oncogenes and tumor suppressor genes are often relevant for tumor classification, and warrant extensive investigation to enhance the understanding of carcinogenesis. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 90000 |
| OTHER TESTS | |||||||
| CL-NGS-06 | SENsi-TvR Human Mitochondria panel | coding and noncoding somatic mitochondrial DNA mutations are routinely detected in tumor samples having role in oncogenesis and metastasis. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 30000 |
| CL-NGS-11 | SENsi-TvR Cardiomyopathy panels | 58 key genes mutated in hereditary cardiomyopathy including hypertrophy and dilated. Also includes genes for rarer forms of familial cardiomyopathy, including some inherited diseases with broader phenotypes. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 50000 |
| CL-NGS-12 | SENsi-TvR Inherited Genetic Disease predisposition Panel | 298 genes in which mutations are responsible for a number of inherited diseases. The gene panel includes genes mutated in 164 of the most deleterious and most prevalent (at least 5 in one million) recessively (autosomal or X-linked) inherited disorders. It also includes 145 genes commonly mutated in 88 inherited oncogenic diseases. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 90000 |
| CL-NGS-14 | SENsi-TvR Pharmacogenomics Panel | 31 drug metabolism genes whose haplotypes affect individuals’ abilities to metabolize drugs and other foreign chemicals. The known inherited mutations detected by this panel affect the ability to absorb, distribute, metabolize and eliminate such compounds in ways that can lead to toxicity (ADMET). Patient genotypes are usually categorized into the predicted phenotypes of ultra-rapid, extensive, intermediate or poor metabolizer. | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 6 weeks | 40000 |
| CL-NGS-CUSTOM | SENsi-TvR Customized panels | Any number of genes from 2 to 400 genes coverage | NGS | gDNA /Blood | 2ugDNA/ 5 ml blood (EDTA tube) | 8 weeks | Variable |
